CD8A and neoplasm: Since the release of CD8 cells from checkpoint inhibition by PD-1 therapies results in rapid tumor shrinkage [10], it seems reasonable to assume that anti-tumor T cells present at the initiation of PD-1 therapies are critical to the initial tumor response.